03/02/2022 - Institutional news
On 4 February, the XXIV Olympic Winter Games will be inaugurated in Beijing, which this year will be held under very strict COVID-19 control protocols. Three scientists from the IMIM Anti-Doping Laboratory, Rosa Ventura, Sergi Coll and Lídia Requena, will be travelling to Beijing to work in the Olympic laboratory. Rosa Ventura will be involved in the management and supervision group, Sergi Coll will be working on the detection of anabolic steroids, and Lídia Requena will be concentrating on the detection of hormones (erythropoietin, growth hormone). The Beijing Laboratory will analyse 3000 samples over the Olympic Games and another 600 during the Paralympic Games. This high volume of samples requires a great deal of analytical equipment and a large number of specialised professionals organised into shifts working around the clock.
22/02/2022 - Covid-19
Dr. Esther Barreiro is the editor of the book 'Physiopathology of COVID-19 in different organs and systems', published by Elsevier. It is a work and study manual for people interested in learning more about this disease. The experts from Hospital del Mar have played a leading role in the new publication by Elsevier, Physiopathology of COVID-19 in different organs and systems, the first manual that analyses, with the help of various specialists, the effects caused by SARS-CoV-2, its mechanisms of infection, treatment, and sequelae. Dr. Esther Barreiro, consultant physician in the Pneumology Department at Hospital del Mar, researcher at the Hospital del Mar Medical Research Institute (IMIM), and associate professor at Pompeu Fabra University, is the editor.
31/01/2022 - General information
Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.
28/01/2022 - General information
The renowned chef gave an online session in which she explained that it is possible to eat well and healthily and still enjoy food. The talk, organised by the Hospital del Mar Medical Research Institute's Neurosciences programme, is part of the cognitive and social stimulation sessions for volunteers in the PENSA project on the prevention of cognitive impairment. Can you eat healthily and still get excited about what you eat? The answer is yes. This was explained by Ada Parellada, the chef and director of Restaurant Semproniana and 2016 Creu de Sant Jordi winner, who this morning visited the facilities at the Hospital de Mar Medical Research Institute (IMIM) as a guest of the Institute's Neuroscience Programme. Her visit was part of the PENSA project, promoted by the programme, in collaboration with the Barcelonaβeta Brain Research Centre from the Pasqual Maragall Foundation.
27/01/2022 - Press release
This is a new valid marker for diagnosing this type of tumour, one of the cancers with the worst prognosis. It is, in fact, the third leading cause of cancer death in developed countries. The study, published in the journal eBioMedicine, was led by researchers from the Hospital del Mar Medical Research Institute and IBB-CSIC-IDIBAPS. Their results point to a protein present in tumour cells as an indicator of pancreatic cancer in early stages of the disease. This marker can be detected through a simple blood test, facilitating its application in clinical practice. A team of researchers from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and IIBB-CSIC-IDIBAPS have identified a new viable early diagnostic marker for the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. The study has been published in the journal eBioMedicine, from The Lancet group, and may represent an important step in the early detection and treatment of this type of tumour, with one of the worst prognoses. Doctors and researchers from the Digestology and Medical Oncology Departments at Hospital del Mar, as well as from the Spanish National Cancer Research Centre (Centro Nacional de Investigaciones Oncológicas; CNIO), the Ramón y Cajal Institute for Health Research (Instituto Ramón y Cajal de Investigación Sanitaria; IRYCIS) and CIBER also collaborated in the study.
Més informació "New diagnostic marker for pancreatic cancer identified"
26/01/2022 - General information
The technique achieves good results in terms of toxicity, the preservation of the physical appearance and patient ratings when used for partial breast irradiation compared to its use in combination with large doses of fractionated whole-breast irradiation. Patients with early-stage breast cancer more positively evaluate treatment with partial intraoperative radiotherapy of the breast than the approach that uses the same technique in combination with whole-breast irradiation divided into large doses. This is highlighted in a study published in the journal Clinical and Translational Oncology, led by the Radiation Oncology Service and the Functional Breast Pathology Unit at Hospital del Mar as well as researchers in the Radiation Oncology Research Group at the Hospital del Mar Medical Research Institute.
Més informació "Partial intraoperative radiotherapy in breast cancer, more highly rated by patients"
25/01/2022 - General information
A study by CiSAL and CIBERESP shows that, once they have returned to work, they work at a lower rate than those who have not suffered from the disease. Men and women who had no sick leave or who were on sick leave for other illnesses were at least 9% more likely to continue working compared to workers who took cancer-related sick leave, according to this study carried out in Catalonia and published in 'Scientific Reports'. Not being able to work when you can and want to leads to a loss of self-esteem and social relationships, which can make recovering from cancer psychologically difficult", explains Fernando G. Benavides, the coordinator of the study.
21/01/2022 - Covid-19
12% of patients admitted for COVID-19 who also suffer heart damage need to be readmitted or die within the first year after recovering from the disease. In contrast, this occurs in only 1% of those who do not suffer heart damage during the SARS-CoV-2 infection, according to a study published in the Journal of Clinical Medicine. These people have a baseline situation that is aggravated by previous pathologies such as high blood pressure, chronic renal failure and episodes of heart failure. The authors of the study recommend routine screening for heart damage markers in the blood of patients admitted for COVID-19 to be able to carefully monitor these problems in the long term. Patients who suffer heart damage during a COVID-19 infection are more likely to need to be readmitted to hospital or to die than those who survive the disease without suffering this. This has been revealed by a study led by researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER in Cardiovascular Diseases (CIBERCV), which has been published in the Journal of Clinical Medicine.
Més informació "Cardiac damage in COVID-19 patients is an indicator of poor long-term prognosis"
20/01/2022 - Institutional news
The head of the Gastrointestinal Surgery Section of the Surgery Service of the Hospital del Mar and coordinator of the Gastroesophageal Carcinogenesis Research Group of the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), thus becomes the only surgeon in the State to be an honorary member of this institution, in recognition of his career. Dr. Manuel Pera has become an honorary member of the European Board of Upper Gastrointestinal Surgery, within the European Union of Medical Specialists (UEMS) at the proposal of the institution's examining committee. So far, among the more than forty professionals who have obtained the Board, only three other surgeons from the State have managed to become fellows of the entity. Dr. Pera is the first to do so as an honorary member.
18/01/2022 - General information
The predoctoral researcher Lilian Boll from the Evolutionary Genomics Research Group of the GRIB (IMIM-UPF) has obtained one of the 65 grants of the INPhINIT PhD Program of La Caixa Foundation for her project "Identification of neo-epitopes in cancer derived from non-canonical proteins and their potential use in immunotherapy" to study neoantigens. Neoantigens are tumor-specific antigens generated by mutations in tumor cells, which are only expressed in tumor cells. "One of the approaches in immunotherapy is to block cellular checkpoints so that the immune system recognizes tumor cells by their neoantigens," explains Lilian Boll.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
